Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

GreenLight Biosciences Q1 EPS $(0.19) Beats $(0.23) Estimate, Sales $3.82M Beat $1.00M Estimate; Cash And Equivalents Of $32.4M Will Be Sufficient To Fund Planned Operating Expenses And Capital Expenditures, Into Q2 Of 2023

Author: Benzinga Newsdesk | May 11, 2023 07:32am
GreenLight Biosciences (NASDAQ:GRNA) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $3.82 million which beat the analyst consensus estimate of $1.00 million by 282.00 percent. This is a 1.39K percent increase over sales of $257.00 thousand the same period last year.

Posted In: GRNA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist